Turtle Creek Wealth Advisors LLC Grows Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Turtle Creek Wealth Advisors LLC boosted its position in Zoetis Inc. (NYSE:ZTS) by 2.2% in the 3rd quarter, according to its most recent filing with the SEC. The firm owned 30,521 shares of the company’s stock after acquiring an additional 664 shares during the period. Zoetis comprises approximately 1.2% of Turtle Creek Wealth Advisors LLC’s holdings, making the stock its 25th biggest holding. Turtle Creek Wealth Advisors LLC’s holdings in Zoetis were worth $5,963,000 at the end of the most recent quarter.

Several other institutional investors also recently made changes to their positions in ZTS. Dorsey & Whitney Trust CO LLC grew its stake in shares of Zoetis by 16.0% during the 1st quarter. Dorsey & Whitney Trust CO LLC now owns 4,643 shares of the company’s stock valued at $786,000 after buying an additional 641 shares during the period. Nwam LLC grew its stake in shares of Zoetis by 16.0% during the 1st quarter. Nwam LLC now owns 4,962 shares of the company’s stock valued at $836,000 after buying an additional 684 shares during the period. M&G Plc acquired a new position in shares of Zoetis during the 1st quarter valued at $19,819,000. Intech Investment Management LLC lifted its holdings in shares of Zoetis by 94.6% during the 1st quarter. Intech Investment Management LLC now owns 2,320 shares of the company’s stock valued at $393,000 after acquiring an additional 1,128 shares in the last quarter. Finally, Vanguard Group Inc. lifted its holdings in shares of Zoetis by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 40,749,571 shares of the company’s stock valued at $6,895,235,000 after acquiring an additional 414,605 shares in the last quarter. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Up 0.3 %

Shares of ZTS traded up $0.51 during midday trading on Friday, hitting $175.14. The company had a trading volume of 3,426,474 shares, compared to its average volume of 2,672,116. The company’s 50 day moving average price is $187.09 and its 200 day moving average price is $180.08. The stock has a market cap of $79.02 billion, a price-to-earnings ratio of 32.92, a PEG ratio of 2.68 and a beta of 0.90. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26.

Zoetis (NYSE:ZTS) last released its earnings results on Monday, November 4th. The company reported $1.58 earnings per share for the quarter, topping the consensus estimate of $1.46 by $0.12. The company had revenue of $2.40 billion during the quarter, compared to the consensus estimate of $2.29 billion. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company’s revenue was up 11.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $1.36 EPS. On average, equities research analysts predict that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 3rd. Shareholders of record on Thursday, October 31st will be issued a $0.432 dividend. The ex-dividend date of this dividend is Thursday, October 31st. This represents a $1.73 dividend on an annualized basis and a yield of 0.99%. Zoetis’s dividend payout ratio is currently 32.52%.

Wall Street Analyst Weigh In

ZTS has been the topic of several recent research reports. Stifel Nicolaus lifted their target price on shares of Zoetis from $200.00 to $210.00 and gave the company a “buy” rating in a report on Wednesday, September 18th. Argus upgraded shares of Zoetis to a “strong-buy” rating in a report on Friday, August 9th. JPMorgan Chase & Co. lifted their target price on shares of Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, October 11th. Piper Sandler lifted their target price on shares of Zoetis from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Wednesday, August 14th. Finally, BTIG Research boosted their price objective on shares of Zoetis from $220.00 to $225.00 and gave the stock a “buy” rating in a report on Monday, August 12th. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $221.44.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.